Dali Pharmaceutical Co Ltd
Dali Pharmaceuticalco.,Ltd researches, develops, produces, and sells pharmaceutical products in China. It develops Chinese and Western medicine injection. The company's products include xingnaojing, shenmai, and astragalus injections, as well as citicoline injections. It also has patents, including invention patents and utility models. The company was founded in 1996 and is headquartered in Dali,… Read more
Market Cap & Net Worth: Dali Pharmaceutical Co Ltd (603963)
Dali Pharmaceutical Co Ltd (SHG:603963) has a market capitalization of $35.33 Million (CN¥259.25 Million) as of March 19, 2026. Listed on the SHG stock exchange, this China-based company holds position #28422 globally and #4668 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dali Pharmaceutical Co Ltd's stock price CN¥1.18 by its total outstanding shares 219700000 (219.70 Million).
Dali Pharmaceutical Co Ltd Market Cap History: 2017 to 2025
Dali Pharmaceutical Co Ltd's market capitalization history from 2017 to 2025. Data shows change from $382.72 Million to $35.33 Million (-22.98% CAGR).
Dali Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dali Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.08x
Dali Pharmaceutical Co Ltd's market cap is 4.08 times its annual revenue
1.00x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $382.72 Million | $272.74 Million | $44.45 Million | 1.40x | 8.61x |
| 2018 | $205.58 Million | $401.48 Million | $10.70 Million | 0.51x | 19.21x |
| 2019 | $258.77 Million | $294.32 Million | $13.51 Million | 0.88x | 19.16x |
| 2020 | $232.21 Million | $213.58 Million | $3.23 Million | 1.09x | 71.85x |
| 2021 | $264.70 Million | $171.49 Million | -$41.89 Million | 1.54x | N/A |
| 2022 | $391.06 Million | $132.34 Million | -$17.70 Million | 2.95x | N/A |
| 2023 | $355.72 Million | $87.27 Million | -$20.03 Million | 4.08x | N/A |
Competitor Companies of 603963 by Market Capitalization
Companies near Dali Pharmaceutical Co Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Dali Pharmaceutical Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Dali Pharmaceutical Co Ltd Historical Marketcap From 2017 to 2025
Between 2017 and today, Dali Pharmaceutical Co Ltd's market cap moved from $382.72 Million to $ 35.33 Million, with a yearly change of -22.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | CN¥35.33 Million | -51.24% |
| 2024 | CN¥72.46 Million | -79.63% |
| 2023 | CN¥355.72 Million | -9.04% |
| 2022 | CN¥391.06 Million | +47.74% |
| 2021 | CN¥264.70 Million | +13.99% |
| 2020 | CN¥232.21 Million | -10.26% |
| 2019 | CN¥258.77 Million | +25.87% |
| 2018 | CN¥205.58 Million | -46.28% |
| 2017 | CN¥382.72 Million | -- |
End of Day Market Cap According to Different Sources
On Feb 6th, 2026 the market cap of Dali Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $35.33 Million USD |
| MoneyControl | $35.33 Million USD |
| MarketWatch | $35.33 Million USD |
| marketcap.company | $35.33 Million USD |
| Reuters | $35.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.